SPONTAN prescribed to First Patient Under TGA
Released
Released
Announcement PDF
SPONTAN® prescribed to First Patient Under TGA Special Access
Scheme
5 August 2024
Highlights:
•
•
•
First patients receive SPONTAN® under the Therapeutic Goods Administration (TGA) Special Access
Scheme
Demonstrates potential for SPONTAN in an unmet fast-acting, on-demand erectile dysfunction (ED)
treatment market
Internationally recognised Key Opinion Leader (KOL) now actively engaged in prescribing SPONTAN
o Enables strategic market introduction and collection of real-world data
o Platform to share experiences at international conferences and scientific publications
LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”), is pleased to announce that SPONTAN has been
prescribed to the first patients under the Therapeutic Goods Administration’s (“TGA”) Special Access Scheme
(“SAS”).
Patients were prescribed by the Restorative Sexual Health Clinic (RSHC), which provides evidence-based care to
help individuals achieve optimal sexual function and improve intimate relationships. RSHC was founded by
Melissa Hadley Barrett, a Nurse Practitioner/Sexologist with extensive experience in primary care. Melissa is a
sought-after speaker and educator for health professionals and community members to increase knowledge and
education around sexual health and has been published in international peer-reviewed journals.
LTR Pharma Chairman, Lee Rodne said: “The use of SPONTAN under the early access program marks a watershed
moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential
to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience
with SPONTAN.”
Key Opinion Leader Involvement
LTR’s KOL strategy allows the Company to introduce SPONTAN in a strategic manner through medical leaders in
this space. This approach enables LTR to gather real-world data and raise awareness within the medical
community, paving the way for broader patient access in the future.
Ms Hadley Barrett’s RSHC team uses SPONTAN for select patients who can benefit from a fast-acting nasal spray
treatment for ED.
The use of SPONTAN under the SAS program aligns with LTR Pharma's KOL-led methodology for the sustainable
introduction of this product to the market. It supports:
•
•
•
•
Strategic introduction to the market.
Collection of real-world data by highly experienced medical professionals.
Opportunity for KOLs to share experiences at international conferences and in publications.
Build awareness and knowledge within the wider medical community.
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Restorative Sexual Health Clinic’s founder, Melissa Hadley Barrett, said, “We see SPONTAN as a valuable
addition to our therapeutic capability. SPONTAN complements our holistic approach, offering our patients an innovative
option to help address their sexual health concerns and enhance overall well-being.”
Special Access Scheme
The TGA’s Special Access Scheme enables health practitioners to access unapproved therapeutic goods for
individual patients, assessed case-by-case. This milestone marks a pivotal advancement in the Company’s strategy
to introduce SPONTAN to the market through a meticulously managed, KOL-driven approach. The SAS program
facilitates off-market compassionate use of SPONTAN for patients with unmet medical needs, as determined by
qualified healthcare professionals.
-EndsThis announcement has been approved by the Board of Directors.
About LTR Pharma
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an
innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that
can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product
SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of
a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of
the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control
over the timing, spontaneity, and enjoyment of sexual experiences.
For further information please contact:
Haley Chartres
Media Relations
haley@hck.digital
Peter McLennan
Investor Relations
investors@ltrpharma.com
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Share your feedback
Discover